Print

Neoprobe Corporation (NEOP) Forms Subsidiary To Develop Cellular Therapy Technology; Technology Provided Positive Clinical Results In Variety Of Diseases 
10/19/2005 5:12:24 PM

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has formed a new corporation, CIRA Biosciences, Inc. (CIRA Bio), to explore the development of patient specific cellular therapies that have shown positive patient responses in a variety of clinical settings. CIRA Bio will combine Neoprobe's Activated Cellular Therapy (ACT) technology for patient specific oncology treatment with similar technology licensed from CIRA LLC for treating viral (HIV/AIDS and hepatitis) and autoimmune diseases. Following a strategic assessment of the technology by a third party, CIRA Bio intends to raise capital, in the second half of 2005, to support the formal re-activation of development activities surrounding these technologies.
//-->